How to Choose Pharma Filling Equipment That Actually Works

Every pharmaceutical filling machine looks impressive in a brochure. Clean stainless steel. Precise dosing claims. A photo of the machine running flawlessly in a cleanroom. What the brochure doesn’t show you is the CIP cycle that takes four hours longer than expected, the smoke study that reveals turbulence over your open vials, or the control software that records batch data but doesn’t generate the audit trail your QA team needs for 21 CFR Part 11 compliance.

At MachineLab, we design and build filling systems in Wexford for pharma, biopharma, and life sciences manufacturers. We’ve seen the gap between what’s promised on paper and what actually performs on a production floor. This guide is built from that experience — and from watching what goes wrong when the wrong equipment gets specified.

Start with the physics, not the catalogue

The single most important decision in specifying automated filling equipment is matching the dosing technology to your product’s physical behaviour. Get this wrong and no amount of software tuning will fix it.

Here’s the opinion that matters: for most Irish biopharma operations filling biologics into vials, peristaltic technology with single-use fluid paths is the right starting point. The combination of gentle handling, rapid changeover, and elimination of cleaning validation makes it operationally superior for the multi-product, small-to-mid-batch reality of modern contract manufacturing. Piston fillers remain essential for high-viscosity applications, and net weight systems are non-negotiable for high-value fills where giveaway tolerance must be minimised. But if someone is trying to sell you a traditional piston filler for a monoclonal antibody, ask them how they plan to validate the CIP for your product-contact surfaces between batches — and watch how long the answer takes.

Annex 1 changed the game — has your specification caught up?

The revised EU GMP Annex 1 came into force in August 2023, and it fundamentally altered what regulators expect from sterile filling operations. The document expanded from 16 to 59 pages — that’s not a minor update. It’s a rewrite.

The most significant change is the requirement for a site-specific Contamination Control Strategy (CCS) that connects every control measure — from raw material qualification to the filling operation itself — into a documented, risk-based framework. Your automated filling equipment is no longer evaluated in isolation; it must demonstrably integrate into this holistic strategy.

What this means in practice for equipment specification: Annex 1 now explicitly highlights automation and robotic systems as “appropriate technologies” that reduce or eliminate glove-based interventions in barrier systems. The regulation also introduces the “First Air” principle — requiring that filtered air reaches exposed product and product-contact surfaces without interruption. This has direct implications for filling head design: your nozzle holders and needle guides must be aerodynamically profiled to avoid creating turbulence over open containers.

RABS vs. isolators: what’s actually right for your operation?

Both barrier technologies are acceptable under Annex 1, but they serve different operational profiles. Isolators provide hermetically sealed environments with VHP (vaporised hydrogen peroxide) decontamination — the highest sterility assurance and the direction the industry is heading. RABS use rigid physical barriers with high-velocity unidirectional airflow, requiring a higher-grade background environment (typically Grade B) and carrying more risk from glove-port interventions.

Our view: for new greenfield installations, isolator-based systems are the defensible long-term investment. For existing facilities where a full isolator retrofit isn’t feasible, well-designed RABS with automated interventions can meet Annex 1 requirements — but the CCS documentation burden is heavier. Either way, your filling equipment manufacturer needs to design the machine architecture around the barrier technology, not bolt barrier technology onto a standard machine after the fact.

The small-batch reality most filling machines ignore

The pharmaceutical industry’s shift toward personalised medicine, cell and gene therapies, and targeted biologics has created a problem that traditional filling equipment wasn’t designed to solve: how do you run a batch of 500 vials efficiently on a machine designed for 50,000?

The answer, increasingly, involves three elements working together: Ready-to-Use (RTU) containers that arrive pre-washed and depyrogenated (eliminating the need for washing tunnels), single-use fluid paths that eliminate CIP/SIP between products, and robotic handling systems that can be reprogrammed for different container formats without mechanical retooling.

This is where custom-designed filling systems demonstrate their value over catalogue equipment. A standard high-speed rotary filler is optimised for one thing: throughput. It runs beautifully at 300 vials per minute on a single product format. But ask it to handle four different vial sizes across the week, with validated changeovers between each, and the OEE numbers collapse under changeover time and revalidation overhead.

A purpose-built filling system designed for flexibility — with servo-driven format parts, recipe-driven changeover protocols, and tooling designed for your actual container portfolio — can reduce format changes from hours to minutes. For CDMOs and emerging therapy manufacturers in Ireland, that flexibility isn’t a nice-to-have. It’s the business model.

The questions your supplier should answer before you sign

After years of watching filling equipment specifications go right and wrong, these are the questions we think matter most — and that most brochures don’t answer:

How does the machine integrate into our Contamination Control Strategy? Post-Annex 1, this is the question. Your filling equipment doesn’t exist in a regulatory vacuum. The supplier should be able to articulate how their machine’s design — airflow management, surface materials, monitoring integration — supports your site-wide CCS.

What’s the actual changeover time between our two most different formats? Not the changeover time between two similar vials. The changeover between your 2mL vial and your 20mL cartridge. That’s the number that determines your real-world OEE.

Does the control system generate 21 CFR Part 11 compliant audit trails natively? “We can add that later” is not an acceptable answer. Electronic batch records with secure timestamps, unique user IDs, and tamper-evident audit trails must be designed into the control architecture, not retrofitted.

Can you show me CFD analysis or smoke study evidence for the filling zone? If the answer is no, you’re gambling on whether your filling heads create turbulence that could compromise sterility — and an inspector will eventually ask the same question.

What documentation do I receive? A complete IQ/OQ/PQ template package, full FAT/SAT protocols, P&IDs, electrical schematics, and PLC source code. If the supplier won’t hand over the source code, you’re locked into a relationship by lack of information — not by quality of service.

The right automated filling machine isn’t the fastest, the cheapest, or the most expensive. It’s the one that integrates into your regulatory strategy, handles your actual product portfolio without compromise, and comes from a team that understands the difference between a specification sheet and a production floor. If you’re navigating this decision — whether for a new line, a capacity expansion, or a replacement of aging equipment — we’d welcome the conversation.